Informed Prostate Cancer Patient Support

This graphic shows the significant difference in 5-year overall survival rates between patients who received local treatments (radical prostatectomy at 67.4% and brachytherapy at 52.6%) compared to those who received no surgical or radiation treatment (22.5%). New Research Suggests Local Treatment May Benefit Metastatic Prostate Cancer Patients For Immediate Release - Prostate Cancer Support Group Newsletter In a potentially practice-changing development, new research suggests that treating the primary tumor in men with metastatic prostate cancer may significantly improve survival rates, challenging current treatment protocols. A recent study published in Nature Reviews Urology by researchers Lorenzo Tosco and Hendrik Van Poppel from University Hospitals Leuven has found that patients with metastatic prostate cancer who received local treatments had substantially better survival outcomes than those who didn't. Surprising Survival Benefits The retrospective analysis examined da...

Race, Ethnicity, Lifestyle Mortality for Localized PC Patients Does Lifestyle Affect Prostate Cancer Outcomes? Healthy Lifestyle Choices Linked to Longer Survival in Nonmetastatic Prostate Cancer Patients A recent study published in JAMA Network Open highlights the role of healthy lifestyle choices in improving overall survival among men with nonmetastatic prostate cancer. Conducted by researchers including Dr. Anqi Wang and colleagues, this study analyzed data from the Multiethnic Cohort Study to determine the impact of postdiagnostic lifestyle and dietary behaviors on survival rates. Key Findings: The study followed 2,603 men from diverse racial and ethnic backgrounds for a median of 10.9 years. It found that: A higher 2021 Prostate Cancer Behavior Score was associated with a 31% lower risk of all-cause mortality and a 33% lower risk of cardiovascular disease (CVD)-related mortality . Among African American participants, a healthier lifestyle was linked to a 54% lower risk of pros...

Skip Lymph Node Disection During Surgery for Medium Risk PC New Research Suggests PLND May Be Unnecessary for Some Prostate Cancer Patients A recent study published in the Wiley Online Library offers promising news for men with intermediate-risk prostate cancer. Researchers have found that pelvic lymph node dissection (PLND) – a common but invasive procedure performed during radical prostatectomy – may be safely omitted in certain patients without compromising early cancer outcomes. The Study at a Glance Researchers evaluated nearly 400 patients with intermediate-risk prostate cancer who underwent radical prostatectomy (RP) between 2014 and 2024. They specifically focused on patients who had negative lymph nodes according to PSMA PET scans, a newer and more accurate imaging technique. The study compared two groups of patients: those who underwent RP with PLND and those who had RP alone without PLND. After careful statistical matching to ensure fair comparison, researchers found no ...

  Australian Clinical Trials Recruiting mCRPC Men Clinical Trials Now Recruiting Men with Advanced Prostate Cancer in Australia For men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) in Australia, several clinical trials are currently seeking participants. These studies aim to explore innovative treatments and improve patient outcomes. Below is an overview of notable trials, including their locations, drug information, and links to more details: 1. ANZadapt Trial Study Focus: This Phase II randomized controlled trial compares patient-specific adaptive therapy versus continuous treatment with Abiraterone or Enzalutamide in mCRPC patients. Locations: New South Wales (NSW), Victoria (VIC), Queensland (QLD), South Australia (SA), and Western Australia (WA). Drug Background: Abiraterone and Enzalutamide are standard treatments for mCRPC, working by inhibiting androgen receptor signaling. This trial investigates whether adaptive dosing strategies can en...

  Clinical Trials Recruiting Men with Advanced Prostate Cancer in California For men with metastatic castration-resistant prostate cancer (mCRPC) residing in Southern California outside of San Diego, several clinical trials are currently seeking participants. These studies aim to explore new treatment options and improve patient outcomes. Below is an overview of notable trials, including their locations and links to more information: 1. Combination Therapy with ZEN003694 and Enzalutamide Study Focus: This Phase 2b study evaluates the efficacy of combining ZEN003694, a bromodomain inhibitor, with enzalutamide, a standard therapy, in patients with mCRPC. Location: University of California, San Francisco (UCSF), San Francisco, CA. Details: ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer 2. PSMA-Directed Targeted Alpha Therapy with FPI-2265 Study Focus: This Phase 2 trial investigates the safety and efficacy of FPI-2265,...

UC San Diego Recruiting Participants for Advanced Prostate Cancer Clinical Trials The University of California, San Diego (UCSD) is currently enrolling men with advanced prostate cancer (metastatic castration-resistant prostate cancer, or mCRPC) in several promising clinical trials. These studies aim to test new treatments that may improve outcomes and quality of life for patients. Here’s what you need to know: 1. Abivertinib and Abiraterone Combination Trial What’s being tested? This study is looking at whether adding abivertinib, a targeted therapy, to the standard prostate cancer drug abiraterone can help slow cancer growth. Who can participate? Men with mCRPC, whether they are new to abiraterone treatment or have already tried it. Timeline: The trial is expected to run until January 2028. Why it matters: Abivertinib works differently from standard prostate cancer treatments and may help patients whose cancer has become resistant to other therapies. 2. Cabozantinib and Nivolumab...